WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFujian Medical University

About this trial

Primary hyperparathyroidism is usually cured by removing the single over-active parathyroid adenoma. During surgery, however, surgeons often see a thin rim of normal parathyroid tissue that still "glows" under a near-infrared parathyroid tissue sensor (PTS). It is unclear whether keeping this tissue in place helps preserve hormone function or whether it leaves behind cells that could become over-active again.

The WHITE CAP study will compare two common surgical choices:

Preservation strategy - the surgeon removes only the adenoma and leaves the glowing rim of normal tissue untouched.

En-bloc strategy - the surgeon removes the adenoma together with the glowing rim; if too little parathyroid tissue remains, a small fragment is transplanted into the forearm muscle.

About 120 adult patients who have a single parathyroid adenoma will be randomly assigned (like tossing a coin) to one of the two strategies. All operations will use the same FDA-cleared PTS camera that shows the glands in real time without dye or radiation.

The main question is whether preserving the normal rim lowers the rate of temporary low blood-calcium (numbness, tingling) during the first two days after surgery. The study will also check long-term results-blood calcium and parathyroid hormone (PTH) levels, symptoms, and any return of the disease-over two years.

The PTS imaging itself is painless and adds only a few minutes to the operation. Risks are the same as for standard parathyroid surgery, and participants can withdraw at any time without affecting their usual care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 to 75 years, able to give informed consent.

Biochemically proven primary hyperparathyroidism (elevated serum calcium and inappropriately high PTH).

Pre-operative imaging (sestamibi scan, 4-phase CT, or ultrasound) concordant with a single parathyroid adenoma.

Planned minimally invasive parathyroidectomy using near-infrared parathyroid tissue sensor (PTS) guidance.

Disqualifiers

Multiple endocrine neoplasia (MEN 1 or 2) or suspicion of multi-gland disease (>1 enlarged gland on imaging).

Prior parathyroid or extensive neck surgery causing distorted anatomy.

Need for simultaneous total thyroidectomy or other major neck procedure.

Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m².

Trial design

Design model

Parallel

Treatments tested in this trial

  • Near-Infrared Parathyroid Tissue Sensor Imaging (PTS)

    Device

    FDA-cleared imager (e.g., Fluobeam LX/PTeye) providing real-time autofluorescence to identify parathyroid tissue during surgery; no dye or radiation.

  • Rim-Preservation Technique

    Procedure/Surgery

    Surgical excision of adenoma while leaving the NIRAF-positive rim of normal parathyroid tissue in situ; minimal defatting to ensure perfusion.

  • En-bloc Resection Technique

    Procedure/Surgery

    Surgical excision of adenoma together with the surrounding NIRAF-positive rim; autotransplant fragment if \< 2 normal glands remain in neck.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Arm A - Rim PreservationExperimental treatment 2 interventions
Group B: Arm B - En-bloc ResectionActive comparator 2 interventions

Trial outcomes

Primary outcomes

1

Incidence of Transient Hypocalcaemia

Proportion of participants whose albumin-corrected serum calcium falls \< 2.00 mmol/L or who require oral/IV calcium ± active vitamin D to maintain normocalcaemia within 48 h post-operatively. Blood samples at 6 h, 24 h, and 48 h will be analysed by a blinded central laboratory.

Time frame
Baseline to 48 hours after surgery (Post-op Day 0-2)

Secondary outcomes

1

Permanent Hypocalcaemia

Need for ongoing calcium ± calcitriol to maintain normocalcaemia at ≥ 6 months after surgery.

Time frame
6 months (±14 days) post-op
2

Parathyroid Hormone (PTH) Recovery ≥ 15 pg/mL

Percentage of patients with serum PTH ≥ 15 pg/mL at 24 h, indicating preserved parathyroid function.

Time frame
24 hours post-op
3

Operative Time

Skin incision to skin closure, recorded by anaesthesia time stamp.

Time frame
Intra-operative (minutes)
4

Estimated Blood Loss

Calculated from suction canister minus irrigation plus soaked swab weight.

Time frame
Intra-operative (mL)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fujian Medical University

Lead sponsor

Fujian Medical University Union Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: